Study of SGR-1505 in Mature B-Cell Neoplasms

Launched by SCHRÖDINGER, INC. · Sep 14, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment called SGR-1505 for patients with various types of mature B-cell cancers, including Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. The main goal of the study is to determine how safe SGR-1505 is, how well people tolerate it, and to find out the highest dose that can be given without serious side effects. The trial is currently looking for participants who are between 65 and 74 years old and have a confirmed diagnosis of one of these cancers. To be eligible, patients should have measurable disease and a good performance status, meaning they are generally able to carry out daily activities.

If you decide to join the trial, you will receive SGR-1505 and be closely monitored for any side effects. This study is important because it could help find new treatment options for patients with difficult-to-treat cancers. However, there are some conditions that might exclude you from participating, such as needing immediate treatment or having certain health issues. It's a chance to contribute to research that may benefit others in the future while also receiving care for your condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subject must have a history of histologically or cytologically confirmed mature B-cell malignancy.
• • Subject must have measurable or detectable disease according to the applicable disease-specific classification system and meet criteria for initiation of treatment.
• • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• • Life expectancy ≥ 12 weeks.
• Exclusion Criteria:
• • The subject is in need of immediate cytoreductive therapy (unless the patient has no remaining treatment choice with potential benefit).
• • Subject has previous invasive malignancy in the last 2 years.
• • Subject has a known allergy to SGR-1505 or excipients of SGR-1505.
• • Subject has symptomatic or active CNS involvement of disease.
• • Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that would place the participant at increased risk to the use of an investigational drug.